Markers in Nonalcoholic Steatohepatitis

Advances in Clinical Chemistry

Volumn 61, Issue , 2013, Pages 67-125

  Armutcu, Ferah ^a   Akyol, Sumeyya ^a   Ucar, Fatma ^b   Erdogan, Serpil ^c   Akyol, Omer ^d  

^a TURGUT OZAL UNIVERSITY   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Adipocytokines; Fibrosis biomarkers; Inflammation; NASH; Oxidative stress

Indexed keywords

EID: 84878657108     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407680-8.00004-X     Document Type: Chapter

References (315)

1. Sheth S.G., Gordon F.D., Chopra S. Nonalcoholic steatohepatitis. Ann. Intern. Med. 1997, 126(2):137-145. Epub 1997/01/15.
2. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55(7):434-438. Epub 1980/07/01.
3. Kopec K.L., Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr. Clin. Pract. 2011, 26(5):565-576. Epub 2011/09/29.
4. Falck-Ytter Y., Younossi Z.M., Marchesini G., McCullough A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 2001, 21(1):17-26. Epub 2001/04/12.
5. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011, 33(5):525-540. Epub 2011/01/05.
6. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am. J. Med. Sci. 2005, 330(6):326-335. Epub 2005/12/16.
7. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2007, 25(8):883-889. Epub 2007/04/04.
8. Williams C.D., Stengel J., Asike M.I., Torres D.M., Shaw J., Contreras M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131. Epub 2010/09/23.
9. Chitturi S., Farrell G.C., Hashimoto E., Saibara T., Lau G.K., Sollano J.D. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 2007, 22(6):778-787. Epub 2007/06/15.
10. Petta S., Muratore C., Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig. Liver Dis. 2009, 41(9):615-625. Epub 2009/02/19.
11. Harrison S.A., Kadakia S., Lang K.A., Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am. J. Gastroenterol. 2002, 97(11):2714-2724. Epub 2002/11/12.
12. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923. Epub 2003/04/02.
13. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110. Epub 1990/11/01.
14. Flegal K.M., Ogden C.L., Wei R., Kuczmarski R.L., Johnson C.L. Prevalence of overweight in US children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index. Am. J. Clin. Nutr. 2001, 73(6):1086-1093. Epub 2001/05/31.
15. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121(3):710-723. Epub 2001/08/28.
16. Kroh M., Liu R., Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg. Endosc. 2007, 21(11):1957-1960. Epub 2007/05/05.
17. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004, 8(3):521-533. viii, Epub 2004/08/28.
18. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395. Epub 2004/11/27.
19. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes. Rev. 2010, 11(6):430-445. Epub 2009/10/23.
20. Basciano H., Federico L., Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr. Metab. 2005, 2(1):5. Epub 2005/02/23.
21. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346(16):1221-1231. Epub 2002/04/19.
22. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler. Thromb. Vasc. Biol. 2004, 24(2):e13-e18. Epub 2004/02/10.
23. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845. Epub 1998/04/18.
24. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl. 1):S99-S112. Epub 2006/02/01.
25. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008, 14(2):72-81. Epub 2008/01/26.
26. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107(5):450-455. Epub 1999/11/24.
27. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35(2):373-379. Epub 2002/02/05.
28. Lim J.S., Mietus-Snyder M., Valente A., Schwarz J.M., Lustig R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 2010, 7(5):251-264. Epub 2010/04/07.
29. Zangar R.C., Novak R.F. Effects of fatty acids and ketone bodies on cytochromes P450 2B, 4A, and 2E1 expression in primary cultured rat hepatocytes. Arch. Biochem. Biophys. 1997, 337(2):217-224. Epub 1997/01/15.
30. Bacon B.R., O'Neill R., Britton R.S. Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 1993, 105(4):1134-1140. Epub 1993/10/01.
31. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 1995, 95(5):2111-2119. Epub 1995/05/01.
32. Yoneda M., Nozaki Y., Endo H., Mawatari H., Iida H., Fujita K., et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig. Dis. Sci. 2010, 55(3):808-814.
33. Uysal S., Armutcu F., Aydogan T., Akin K., Ikizek M., Yigitoglu M.R. Some inflammatory cytokine levels, iron metabolism and oxidant stress markers in subjects with nonalcoholic steatohepatitis. Clin. Biochem. 2011, 44(17-18):1375-1379.
34. Fujita N., Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv. Clin. Chem. 2011, 55:105-132.
35. Dongiovanni P., Fracanzani A.L., Fargion S., Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 2011, 55(4):920-932. Epub 2011/07/02.
36. Diehl A.M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin. Liver Dis. 2004, 8(3):619-638. Epub 2004/08/28.
37. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008, 14(3-4):222-231. Epub 2008/02/01.
38. Mato J.M., Corrales F.J., Lu S.C., Avila M.A. S-adenosylmethionine: a control switch that regulates liver function. FASEB J. 2002, 16(1):15-26.
39. Brunt E.M. Nonalcoholic steatohepatitis. Semin. Liver Dis. 2004, 24(1):3-20. Epub 2004/04/16.
40. Brunt E.M., Neuschwander-Tetri B.A., Oliver D., Wehmeier K.R., Bacon B.R. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 2004, 35(9):1070-1082. Epub 2004/09/03.
41. Takahashi Y., Soejima Y., Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 2012, 18(19):2300-2308. Epub 2012/06/02.
42. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999, 94(9):2467-2474. Epub 1999/09/14.
43. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321. Epub 2005/05/26.
44. Takahashi Y., Inui A., Fujisawa T., Takikawa H., Fukusato T. Histopathological characteristics of non-alcoholic fatty liver disease in children: comparison with adult cases. Hepatol. Res. 2011, 41(11):1066-1074. Epub 2011/11/01.
45. McCullough A.J. Update on nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2002, 34(3):255-262. Epub 2002/03/02.
46. Sass D.A., Chang P., Chopra K.B. Nonalcoholic fatty liver disease: a clinical review. Dig. Dis. Sci. 2005, 50(1):171-180. Epub 2005/02/17.
47. Loria P., Lonardo A., Leonardi F., Fontana C., Carulli L., Verrone A.M., et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig. Dis. Sci. 2003, 48(11):2173-2181. Epub 2004/01/07.
48. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362. Epub 1999/11/26.
49. Abrams G.A., Kunde S.S., Lazenby A.J., Clements R.H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004, 40(2):475-483. Epub 2004/09/16.
50. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11(1):74-80. Epub 1990/01/01.
51. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107(4):1103-1109. Epub 1994/10/01.
52. Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am. J. Gastroenterol. 1999, 94(4):1018-1022. Epub 1999/04/14.
53. Kowdley K.V., Belt P., Wilson L.A., Yeh M.M., Neuschwander-Tetri B.A., Chalasani N., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55(1):77-85.
54. Torres D.M., Harrison S.A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134(6):1682-1698. Epub 2008/05/13.
55. Te Sligte K., Bourass I., Sels J.P., Driessen A., Stockbrugger R.W., Koek G.H. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur. J. Intern. Med. 2004, 15(1):10-21. Epub 2004/04/07.
56. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123(3):745-750. Epub 2002/08/29.
57. Chen J., Talwalkar J.A., Yin M., Glaser K.J., Sanderson S.O., Ehman R.L. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011, 259(3):749-756. Epub 2011/04/05.
58. Mehta S.R., Thomas E.L., Bell J.D., Johnston D.G., Taylor-Robinson S.D. Non-invasive means of measuring hepatic fat content. World J. Gastroenterol. 2008, 14(22):3476-3483. Epub 2008/06/21.
59. Wieckowska A., McCullough A.J., Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46(2):582-589. Epub 2007/07/31.
60. Myers R.P. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann. Hepatol. 2009, 8(Suppl. 1):S25-S33. Epub 2009/06/25.
61. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003, 98(5):960-967. Epub 2003/06/18.
62. Oh S.Y., Cho Y.K., Kang M.S., Yoo T.W., Park J.H., Kim H.J., et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006, 55(12):1604-1609.
63. Adams L.A., Feldstein A.E. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J. Dig. Dis. 2011, 12(1):10-16.
64. Luyckx F.H., Lefebvre P.J., Scheen A.J. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 2000, 26(2):98-106. Epub 2000/05/11.
65. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37(6):1286-1292. Epub 2003/05/30.
66. Chang Y., Ryu S., Sung E., Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin. Chem. 2007, 53(4):686-692.
67. Fracanzani A.L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008, 48(3):792-798. Epub 2008/08/30.
68. Pantsari M.W., Harrison S.A. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J. Clin. Gastroenterol. 2006, 40(7):633-635. Epub 2006/08/19.
69. Schreuder T.C., Verwer B.J., van Nieuwkerk C.M., Mulder C.J. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J. Gastroenterol. 2008, 14(16):2474-2486. Epub 2008/04/30.
70. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117(5):1155-1163. Epub 1999/10/27.
71. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
72. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
73. Nelson J.E., Bhattacharya R., Lindor K.D., Chalasani N., Raaka S., Heathcote E.J., et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007, 46(3):723-729. Epub 2007/08/08.
74. Kumar R., Rastogi A., Maras J.S., Sarin S.K. Unconjugated hyperbilirubinemia in patients with non-alcoholic fatty liver disease: a favorable endogenous response. Clin. Biochem. 2012, 45(3):272-274. Epub 2011/12/27.
75. Hjelkrem M., Morales A., Williams C.D., Harrison S.A. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). Aliment. Pharmacol. Ther. 2012, 35(12):1416-1423.
76. Chang Y., Ryu S., Zhang Y.Y., Son H.J., Kim J.Y., Cho J., et al. A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers. PLoS One 2012, 7(5):e37241.
77. Tomita K., Teratani T., Yokoyama H., Suzuki T., Irie R., Ebinuma H., et al. Serum immunoglobulin A concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig. Dis. Sci. 2011, 56(12):3648-3654.
78. Shah A.G., Lydecker A., Murray K., Tetri B.N., Contos M.J., Sanyal A.J., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009, 7(10):1104-1112.
79. Adams L.A., Lindor K.D., Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2004, 99(7):1316-1320.
80. Vuppalanchi R., Gould R.J., Wilson L.A., Unalp-Arida A., Cummings O.W., Chalasani N., et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2011, 6(1):379-385.
81. Niwa H., Sasaki M., Haratake J., Kasai T., Katayanagi K., Kurumaya H., et al. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol. Res. 2007, 37(11):923-931. Epub 2007/07/06.
82. Angulo P., Alba L.M., Petrovic L.M., Adams L.A., Lindor K.D., Jensen M.D. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J. Hepatol. 2004, 41(6):943-949. Epub 2004/12/08.
83. Parola M., Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxid. Redox Signal. 2011, 15(2):461-483. Epub 2011/01/05.
84. Marra F. NASH: are genes blowing the hits?. J. Hepatol. 2004, 40(5):853-856. Epub 2004/04/20.
85. Lemoine M., Ratziu V., Kim M., Maachi M., Wendum D., Paye F., et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009, 29(9):1431-1438. Epub 2009/05/09.
86. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta 2007, 380(1-2):24-30.
87. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 2003, 14(6):561-566.
88. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 2005, 90(6):3498-3504.
89. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules-adipocyte-derived plasma protein adiponectin. Circulation 1999, 100(25):2473-2476.
90. Copaci I., Micu L., Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. J. Gastrointestin. Liver Dis. 2006, 15(4):363-373. Epub 2007/01/06.
91. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40(1):46-54. Epub 2004/07/09.
92. Polyzos S.A., Toulis K.A., Goulis D.G., Zavos C., Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011, 60(3):313-326. Epub 2010/11/03.
93. Pagano C., Soardo G., Esporito W., Fallo F., Basan L., Donnini D., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol. 2005, 152(1):113-118.
94. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54(1):117-121. Epub 2004/12/14.
95. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med. Sci. Monit. 2003, 9(2):RA55-RA61. Epub 2003/02/26.
96. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000, 102(11):1296-1301.
97. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8(7):731-737.
98. Halaas J.L., Boozer C., BlairWest J., Fidahusein N., Denton D.A., Friedman J.M. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(16):8878-8883.
99. Friedman J.M. The function of leptin in nutrition, weight, and physiology. Nutr. Rev. 2002, 60(10 Pt 2):S1-S14. discussion S68-S84, 5-7. Epub 2002/10/31.
100. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Liddle C., et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 2002, 36(2):403-409.
101. Fishman S., Muzumdar R.H., Atzmon G., Ma X.H., Yang X.M., Einstein F.H., et al. Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J. 2007, 21(1):53-60.
102. Huang W., Dedousis N., O'Doherty R.M. Hepatic steatosis and plasma dyslipidemia induced by a high-sucrose diet are corrected by an acute leptin infusion. J. Appl. Physiol. 2007, 102(6):2260-2265.
103. Ikejima K., Honda H., Yoshikawa M., Hirose M., Kitamura T., Takei Y., et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34(2):288-297.
104. Ikejima K., Takei Y., Honda H., Hirose M., Yoshikawa M., Zhang Y.J., et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122(5):1399-1410.
105. Aleffi S., Petrai I., Bertolani C., Parola M., Colombatto S., Novo E., et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005, 42(6):1339-1348.
106. Ding X.K., Saxena N.K., Lin S.B., Xu A., Srinivasan S., Anania F.A. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 2005, 166(6):1655-1669.
107. Xu A.M., Wang Y., Keshaw H., Xu L.Y., Lam K.S.L., Cooper G.J.S. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003, 112(1):91-100.
108. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125(6):1796-1807.
109. Saxena N.K., Sharma D., Ding X.K., Lin S.B., Marra F., Merlin D., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67(6):2497-2507.
110. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312. Epub 2001/02/24.
111. Kamada Y., Takehara T., Hayashi N. Adipocytokines and liver disease. J. Gastroenterol. 2008, 43(11):811-822.
112. Arner P. Resistin: yet another adipokine tells us that men are not mice. Diabetologia 2005, 48(11):2203-2205. Epub 2005/09/30.
113. Luo R., Li X., Jiang R., Gao X., Lu Z., Hua W. Serum concentrations of resistin and adiponectin and their relationship to insulin resistance in subjects with impaired glucose tolerance. J. Int. Med. Res. 2012, 40(2):621-630.
114. Banerjee R.R., Rangwala S.M., Shapiro J.S., Rich A.S., Rhoades B., Qi Y., et al. Regulation of fasted blood glucose by resistin. Science 2004, 303(5661):1195-1198.
115. Meier U., Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin. Chem. 2004, 50(9):1511-1525.
116. Bertolani C., Sancho-Bru P., Failli P., Bataller R., Aleffi S., DeFranco R., et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am. J. Pathol. 2006, 169(6):2042-2053. Epub 2006/12/07.
117. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007, 178(3):1748-1758. Epub 2007/01/24.
118. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006, 580(12):2917-2921. Epub 2006/05/06.
119. Singla P., Bardoloi A., Parkash A.A. Metabolic effects of obesity: a review. World J. Diabetes 2010, 1(3):76-88. Epub 2011/05/04.
120. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 27(5):412-421.
121. Gaddipati R., Mitnala S., Padaki N., Mukherjee R.M., Sekaran A., Jayaraj-Mansard M., et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann. Hepatol. 2010, 9(3):266-270.
122. Zhou J., Febbraio M., Wada T., Zhai Y., Kuruba R., He J., et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR gamma in promoting steatosis. Gastroenterology 2008, 134(2):556-567.
123. Gervois P., Fruchart J.C., Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3(2):145-156.
124. Gastaldelli A., Miyazaki Y., Mahankali A., Berria R., Pettiti M., Buzzigoli E., et al. The effect of pioglitazone on the liver-role of adiponectin. Diabetes Care 2006, 29(10):2275-2281.
125. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114(2):147-152.
126. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int. J. Obes. 2004, 28(6):783-789.
127. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006, 355(22):2297-2307.
128. Fujii H., Kawada N. Inflammation and fibrogenesis in steatohepatitis. J. Gastroenterol. 2012, 47(3):215-225.
129. Ikejima K., Okumura K., Kon K., Takei Y., Sato N. Role of adipocytokines in hepatic fibrogenesis. J. Gastroenterol. Hepatol. 2007, 22:S87-S92.
130. Ahima R.S., Lazar M.A. Adipokines and the peripheral and neural control of energy balance. Mol. Endocrinol. 2008, 22(5):1023-1031.
131. Cortez-Pinto H., de Moura M.C., Day C.P. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 2006, 44(1):197-208.
132. De Minicis S., Svegliati-Baroni G. Fibrogenesis in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. 2011, 5(2):179-187.
133. Pessayre D., Berson A., Fromenty B., Mansouri A. Mitochondria in steatohepatitis. Semin. Liver Dis. 2001, 21(1):57-69.
134. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11(2):191-198.
135. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34(6):1158-1163.
136. Beltowski J., Wojcicka G.Y., Jamroz A. Stimulatory effect of leptin on nitric oxide production is impaired in dietary-induced obesity. Obes. Res. 2003, 11(12):1571-1580.
137. Su G.L. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283(2):G256-G265.
138. Beltowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin. Exp. Pharmacol. Physiol. 2012, 39(2):168-178.
139. Armutcu F., Coskun O., Gurel A., Kanter M., Can M., Ucar F., et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin. Biochem. 2005, 38(6):540-547.
140. Tsochatzis E.A., Papatheodoridis G.V., Archimandritis A.J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm. 2009, 2009:831670. Epub 2009/09/16.
141. Lucero D., Zago V., Lopez G.I., Graffigna M., Fainboim H., Miksztowicz V., et al. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin. Chim. Acta 2011, 412(1-2):143-147.
142. Bansal M.B., Kovalovich K., Gupta R., Li W., Agarwal A., Radbill B., et al. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J. Hepatol. 2005, 42(4):548-556.
143. Yamaguchi K., Itoh Y., Yokomizo C., Nishimura T., Niimi T., Fujii H., et al. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab. Invest. 2010, 90(8):1169-1178.
144. Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E., Poli V., et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274(5291):1379-1383.
145. Blindenbacher A., Wang X.Y., Langer I., Savino R., Terracciano L., Heim M.H. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 2003, 38(3):674-682.
146. El-Assal O., Hong F., Kim W.H., Radaeva S., Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell. Mol. Immunol. 2004, 1(3):205-211. Epub 2005/10/13.
147. Tarantino G., Conca P., Pasanisi F., Ariello M., Mastrolia M., Arena A., et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. Eur. J. Gastroenterol. Hepatol. 2009, 21(5):504-511.
148. Larter C.Z., Farrell G.C. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?. J. Hepatol. 2006, 44(2):253-261.
149. Tarantino G., Conca P., Riccio A., Tarantino M., Di Minno M.N., Chianese D., et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?. J. Transl. Med. 2008, 6:72.
150. dela Pena A., Leclercq I.A., Williams J., Farrell G.C. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J. Hepatol. 2007, 46(2):304-313.
151. Esteve E., Ricart W., Fernandez-Real J.M. Adipocytokines and insulin resistance the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 2009, 32:S362-S367.
152. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 2000, 1492(1):203-206.
153. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5(6):415-425. Epub 2007/06/07.
154. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 2010, 53(5):934-940. Epub 2010/08/03.
155. Cheng X., Zhu B., Jiang F., Fan H. Serum FGF-21 levels in type 2 diabetic patients. Endocr. Res. 2011, 36(4):142-148. Epub 2011/10/07.
156. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139(2):456-463.
157. Farrell G.C., van Rooyen D., Gan L., Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012, 6(2):149-171. Epub 2012/05/10.
158. Schwabe R.F., Seki E., Brenner D.A. Toll-like receptor signaling in the liver. Gastroenterology 2006, 130(6):1886-1900.
159. Nomura K., Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2012, 23(3):203-208.
160. Rivera C.A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47(4):571-579.
161. Csak T., Velayudham A., Hritz I., Petrasek J., Levin I., Lippai D., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300(3):G433-G441.
162. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25(51):6680-6684. Epub 2006/10/31.
163. Schwabe R.F., Brenner D.A. Nuclear factor-kappaB in the liver: friend or foe?. Gastroenterology 2007, 132(7):2601-2604.
164. Dela Pena A., Leclercq I., Field J., George J., Jones B., Farrell G. NF-kappa B activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005, 129(5):1663-1674.
165. Brenner D.A., Seki E., Taura K., Kisseleva T., Deminicis S., Iwaisako K., et al. Non-alcoholic steatohepatitis-induced fibrosis: toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol. Res. 2011, 41(7):683-686.
166. Schattenberg J.M., Singh R., Wang Y., Lefkowitch J.H., Rigoli R.M., Scherer P.E., et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43(1):163-172. Epub 2005/12/24.
167. Puri P., Mirshahi F., Cheung O., Natarajan R., Maher J.W., Kellum J.M., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134(2):568-576. Epub 2007/12/18.
168. Larter C.Z., Yeh M.M., Van Rooyen D.M., Brooling J., Ghatora K., Farrell G.C. Peroxisome proliferator-activated receptor-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2012, 27(2):341-350. Epub 2011/09/21.
169. Xu L.L., Warren M.K., Rose W.L., Gong W., Wang J.M. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 1996, 60(3):365-371. Epub 1996/09/01.
170. Cai K., Qi D.F., Hou X.W., Wang O.M., Chen J., Deng B., et al. MCP-1 upregulates amylin expression in murine pancreatic beta cells through ERK/JNK-AP1 and NF-kappa B related signaling pathways independent of CCR2. PLoS One 2011, 6(5):e19559.
171. Hui J.M., Kench J.G., Farrell G.C., George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004, 39(5):1458-1459.
172. Yoneda M., Mawatari H., Fujita K., Iida H., Yonemitsu K., Kato S., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 2007, 42(7):573-582.
173. Negre-Salvayre A., Auge N., Ayala V., Basaga H., Boada J., Brenke R., et al. Pathological aspects of lipid peroxidation. Free Radic. Res. 2010, 44(10):1125-1171.
174. Bonnefont-Rousselot D., Ratziu V., Giral P., Charlotte F., Beucler I., Poynard T., et al. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment. Pharmacol. Ther. 2006, 23(1):91-98.
175. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11(1):81-128.
176. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indexes of lipid-peroxidation and peroxidative tissue-injury. Free Radic. Biol. Med. 1990, 9(6):515-540.
177. Koek G.H., Liedorp P.R., Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin. Chim. Acta 2011, 412(15-16):1297-1305. Epub 2011/04/26.
178. Loguercio C., De Girolamo V., de Sio I., Tuccillo C., Ascione A., Badi F., et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J. Hepatol. 2001, 35(5):568-574.
179. Malaguarnera L., Madeddu R., Palio E., Arena N., Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J. Hepatol. 2005, 42(4):585-591.
180. Chalasani N., Deeg M.A., Crabb D.W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004, 99(8):1497-1502. Epub 2004/08/17.
181. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 2002, 37(1):56-62.
182. George J., Pera N., Phung N., Leclercq I., Yun Hou J., Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 2003, 39(5):756-764. Epub 2003/10/22.
183. Poli G., Albano E., Dianzani M.U. The role of lipid peroxidation in liver damage. Chem. Phys. Lipids 1987, 45(2-4):117-142. Epub 1987/11/01.
184. Bedossa P., Houglum K., Trautwein C., Holstege A., Chojkier M. Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis?. Hepatology 1994, 19(5):1262-1271. Epub 1994/05/01.
185. Parola M., Pinzani M., Casini A., Albano E., Poli G., Gentilini A., et al. Stimulation of lipid-peroxidation or 4-hydroxynonenal treatment increases procollagen-alpha-1 (I) gene-expression in human liver fat-storing cells. Biochem. Biophys. Res. Commun. 1993, 194(3):1044-1050.
186. Milne G.L., Sanchez S.C., Musiek E.S., Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2007, 2(1):221-226. Epub 2007/04/03.
187. Kadiiska M.B., Gladen B.C., Baird D.D., Germolec D., Graham L.B., Parker C.E., et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic. Biol. Med. 2005, 38(6):698-710. Epub 2005/02/22.
188. Zhu M.J., Sun L.J., Liu Y.Q., Feng Y.L., Tong H.T., Hu Y.H., et al. Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis. World J. Gastroenterol. 2008, 14(29):4677-4683. Epub 2008/08/14.
189. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52(1):59-69. Epub 2011/11/09.
190. Videla L.A., Rodrigo R., Orellana M., Fernandez V., Tapia G., Quinones L., et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. 2004, 106(3):261-268.
191. Garcia-Monzon C., Martin-Perez E., Lo Iacono O., Fernandez-Bermejo M., Majano P.L., Apolinario A., et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J. Hepatol. 2000, 33(5):716-724.
192. Baskol G., Baskol M., Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin. Biochem. 2007, 40(11):776-780.
193. La Du B.N., Aviram M., Billecke S., Navab M., Primo-Parmo S., Sorenson R.C., et al. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 1999, 120:379-388.
194. Cassader M., Gambino R., Musso G., Depetris N., Mecca F., Cavallo-Perin P., et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001, 36(10):1117-1124. Epub 2002/01/05.
195. Perlemuter G., Davit-Spraul A., Cosson C., Conti M., Bigorgne A., Paradis V., et al. Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Int. 2005, 25(5):946-953.
196. Nobili V., Pastore A., Gaeta L.M., Tozzi G., Comparcola D., Sartorelli M.R., et al. Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis. Clin. Chim. Acta 2005, 355(1-2):105-111.
197. Yesilova Z., Yaman H., Oktenli C., Ozcan A., Uygun A., Cakir E., et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005, 100(4):850-855.
198. Buss H., Chan T.P., Sluis K.B., Domigan N.M., Winterbourn C.C. Protein carbonyl measurement by a sensitive ELISA method. Free Radic. Biol. Med. 1997, 23(3):361-366. Epub 1997/01/01.
199. Weiss S.J. Tissue destruction by neutrophils. N. Engl. J. Med. 1989, 320(6):365-376. Epub 1989/02/09.
200. Nomoto K., Tsuneyama K., Takahashi H., Murai Y., Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl. Immunohistochem. Mol. Morphol. 2008, 16(1):71-75. Epub 2007/12/20.
201. Toyokuni S., Tanaka T., Hattori Y., Nishiyama Y., Yoshida A., Uchida K., et al. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab. Invest. 1997, 76(3):365-374. Epub 1997/03/01.
202. Kadiiska M.B., Gladen B.C., Baird D.D., Graham L.B., Parker C.E., Ames B.N., et al. Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic. Biol. Med. 2005, 38(6):711-718.
203. Loguercio C., Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic. Biol. Med. 2003, 34(1):1-10. Epub 2002/12/25.
204. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6(1):1-28. Epub 2006/01/13.
205. Ottesen L.H., Harry D., Frost M., Davies S., Khan K., Halliwell B., et al. Increased formation of S-nitrothiols and nitrotyrosine in cirrhotic rats during endotoxemia. Free Radic. Biol. Med. 2001, 31(6):790-798. Epub 2001/09/15.
206. Garcia-Ruiz I., Rodriguez-Juan C., Diaz-Sanjuan T., del Hoyo P., Colina F., Munoz-Yague T., et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006, 44(3):581-591. Epub 2006/08/31.
207. Chen Y., Hozawa S., Sawamura S., Sato S., Fukuyama N., Tsuji C., et al. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem. Biophys. Res. Commun. 2005, 326(1):45-51. Epub 2004/11/30.
208. Armutcu F., Ataymen M., Atmaca H., Gurel A. Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 2008, 46(6):785-790. Epub 2008/07/08.
209. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 2008, 48(6):993-999.
210. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005, 67(5):1739-1742.
211. Sheth S.G., Flamm S.L., Gordon F.D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1998, 93(1):44-48. Epub 1998/02/03.
212. Chitturi S., George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr. Gastroenterol. Rep. 2003, 5(1):18-25. Epub 2003/01/18.
213. Sumida Y., Yoshikawa T., Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol. Res. 2009, 39(3):213-222. Epub 2009/03/06.
214. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114(2):311-318. Epub 1998/02/07.
215. Armutcu F., Uysal S., Aydogan T., Pala K., Ikizek M., Yigitoglu M.R. Some inflammatory cytokine levels and iron metabolism markers in subjects with nonalcoholic steatohepatitis. J. Hepatol. 2011, 54:S331.
216. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102(3):783-788.
217. Harrison-Findik D.D. Gender-related variations in iron metabolism and liver diseases. World J. Hepatol. 2010, 2(8):302-310. Epub 2010/12/17.
218. Chung B., Matak P., McKie A.T., Sharp P. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J. Nutr. 2007, 137(11):2366-2370. Epub 2007/10/24.
219. Fujita N., Sugimoto R., Takeo M., Urawa N., Mifuji R., Tanaka H., et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol. Med. 2007, 13(1-2):97-104. Epub 2007/05/23.
220. Baranova A., Lal P., Birerdinc A., Younossi Z.M. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011, 11:91. Epub 2011/08/19.
221. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115(2):209-218. Epub 2005/02/04.
222. Lemoine M., Serfaty L., Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr. Opin. Infect. Dis. 2012, 25(1):10-16. Epub 2011/12/21.
223. Sebastiani G., Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol. 2006, 12(23):3682-3694.
224. Adams L.A. Biomarkers of liver fibrosis. J. Gastroenterol. Hepatol. 2011, 26(5):802-809. Epub 2011/01/05.
225. Sebastiani G., Vario A., Guido M., Noventa F., Plebani M., Pistis R., et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J. Hepatol. 2006, 44(4):686-693. Epub 2006/02/24.
226. Harrison S.A., Oliver D., Arnold H.L., Gogia S., Neuschwander-Tetri B.A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57(10):1441-1447.
227. Gutkowski K., Hartleb M. Usefulness of non-invasive tools in liver fibrosis assessment. Hepat. Mon. 2008, 8(1):45-50.
228. Gressner A.M., Gao C.F., Gressner O.A. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J. Gastroenterol. 2009, 15(20):2433-2440.
229. Koda M., Matunaga Y., Kawakami M., Kishimoto Y., Suou T., Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45(2):297-306.
230. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4):846-854. Epub 2007/03/30.
231. Zarski J.P., Sturm N., Guechot J., Paris A., Zafrani E.S., Asselah T., et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J. Hepatol. 2012, 56(1):55-62. Epub 2011/07/26.
232. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526. Epub 2003/07/29.
233. Sakugawa H., Nakayoshi T., Kobashigawa K., Yamashiro T., Maeshiro T., Miyagi S., et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 2005, 11(2):255-259. Epub 2005/01/06.
234. Teare J.P., Sherman D., Greenfield S.M., Simpson J., Bray G., Catterall A.P., et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993, 342(8876):895-898. Epub 1993/10/09.
235. Oberti F., Valsesia E., Pilette C., Rousselet M.C., Bedossa P., Aube C., et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997, 113(5):1609-1616. Epub 1997/11/14.
236. Sterling R.K., Lissen E., Clumeck N., Sola R., Correa M.C., Montaner J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43(6):1317-1325. Epub 2006/05/27.
237. Vallet-Pichard A., Mallet V., Nalpas B., Verkarre V., Nalpas A., Dhalluin-Venier V., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007, 46(1):32-36. Epub 2007/06/15.
238. Cales P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42(6):1373-1381. Epub 2005/12/01.
239. Leroy V., Hilleret M.N., Sturm N., Trocme C., Renversez J.C., Faure P., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J. Hepatol. 2007, 46(5):775-782. Epub 2007/02/27.
240. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357(9262):1069-1075. Epub 2001/04/12.
241. Rossi E., Adams L., Prins A., Bulsara M., de Boer B., Garas G., et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem. 2003, 49(3):450-454. Epub 2003/02/26.
242. Halfon P., Bourliere M., Deydier R., Botta-Fridlund D., Renou C., Tran A., et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am. J. Gastroenterol. 2006, 101(3):547-555. Epub 2006/03/18.
243. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 2005, 51(10):1867-1873. Epub 2005/08/02.
244. Becker L., Salameh W., Sferruzza A., Zhang K., ng Chen R., Malik R., et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin. Gastroenterol. Hepatol. 2009, 7(6):696-701. Epub 2009/06/11.
245. Halfon P., Imbert-Bismut F., Messous D., Antoniotti G., Benchetrit D., Cart-Lamy P., et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp. Hepatol. 2002, 1(1):3. Epub 2003/01/23.
246. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol. 2004, 3(1):8. Epub 2004/09/25.
247. Poynard T., Ratziu V., Naveau S., Thabut D., Charlotte F., Messous D., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol. 2005, 4:10. Epub 2005/12/27.
248. Parkes J., Guha I.N., Roderick P., Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J. Hepatol. 2006, 44(3):462-474. Epub 2006/01/24.
249. Gallorini A., Plebani M., Pontisso P., Chemello L., Masiero M., Mantovani G., et al. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. Liver 1994, 14(5):257-264. Epub 1994/10/01.
250. Nobili V., Parkes J., Bottazzo G., Marcellini M., Cross R., Newman D., et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009, 136(1):160-167. Epub 2008/11/11.
251. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127(6):1704-1713. Epub 2004/12/04.
252. Alkhouri N., Carter-Kent C., Lopez R., Rosenberg W.M., Pinzani M., Bedogni G., et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin. Gastroenterol. Hepatol. 2011, 9(2):150-155. Epub 2010/10/05.
253. Stefanovic B., Hellerbrand C., Holcik M., Briendl M., Aliebhaber S., Brenner D.A. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. Mol. Cell. Biol. 1997, 17(9):5201-5209. Epub 1997/09/01.
254. Trinchet J.C., Hartmann D.J., Pateron D., Laarif M., Callard P., Ville G., et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J. Hepatol. 1991, 12(2):139-144. Epub 1991/03/01.
255. Murawaki Y., Ikuta Y., Koda M., Yamada S., Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J. Hepatol. 1996, 24(2):148-154. Epub 1996/02/01.
256. George D.K., Ramm G.A., Walker N.I., Powell L.W., Crawford D.H. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. J. Hepatol. 1999, 31(1):47-52. Epub 1999/07/29.
257. Shimada M., Kawahara H., Ozaki K., Fukura M., Yano H., Tsuchishima M., et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2007, 102(9):1931-1938. Epub 2007/05/22.
258. Murawaki Y., Ikuta Y., Okamoto K., Koda M., Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J. Gastroenterol. 2001, 36(6):399-406. Epub 2001/06/29.
259. Hahn E., Wick G., Pencev D., Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 1980, 21(1):63-71. Epub 1980/01/01.
260. Matsumoto S., Yamamoto K., Nagano T., Okamoto R., Ibuki N., Tagashira M., et al. Immunohistochemical study on phenotypical changes of hepatocytes in liver disease with reference to extracellular matrix composition. Liver 1999, 19(1):32-38. Epub 1999/02/03.
261. Walsh K.M., Fletcher A., MacSween R.N., Morris A.J. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J. Hepatol. 2000, 32(2):325-330. Epub 2000/03/09.
262. Misaki M., Shima T., Yano Y., Sumita Y., Kano U., Murata T., et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin. Chem. 1990, 36(3):522-524. Epub 1990/03/01.
263. Pares A., Deulofeu R., Gimenez A., Caballeria L., Bruguera M., Caballeria J., et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996, 24(6):1399-1403. Epub 1996/12/01.
264. Suzuki A., Angulo P., Lymp J., Li D., Satomura S., Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005, 25(4):779-786. Epub 2005/07/07.
265. Guechot J., Laudat A., Loria A., Serfaty L., Poupon R., Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin. Chem. 1996, 42(4):558-563. Epub 1996/04/01.
266. Kaneda H., Hashimoto E., Yatsuji S., Tokushige K., Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2006, 21(9):1459-1465. Epub 2006/08/17.
267. Fontana R.J., Goodman Z.D., Dienstag J.L., Bonkovsky H.L., Naishadham D., Sterling R.K., et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47(3):789-798. Epub 2008/01/05.
268. Patel K., Nelson D.R., Rockey D.C., Afdhal N.H., Smith K.M., Oh E., et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2008, 6(2):242-247. Epub 2008/01/12.
269. Malik R., Chang M., Bhaskar K., Nasser I., Curry M., Schuppan D., et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009, 24(4):564-568. Epub 2009/04/21.
270. Harvey S., Weisman M., O'Dell J., Scott T., Krusemeier M., Visor J., et al. Chondrex: new marker of joint disease. Clin. Chem. 1998, 44(3):509-516. Epub 1998/03/25.
271. Nojgaard C., Johansen J.S., Christensen E., Skovgaard L.T., Price P.A., Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J. Hepatol. 2003, 39(2):179-186. Epub 2003/07/23.
272. Johansen J.S., Christoffersen P., Moller S., Price P.A., Henriksen J.H., Garbarsch C., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J. Hepatol. 2000, 32(6):911-920.
273. Pizano-Martinez O., Yanez-Sanchez I., Alatorre-Carranza P., Miranda-Diaz A., Ortiz-Lazareno P.C., Garcia-Iglesias T., et al. YKL-40 expression in CD14(+) liver cells in acute and chronic injury. World J. Gastroenterol. 2011, 17(33):3830-3835. Epub 2011/10/12.
274. Tran A., Benzaken S., Saint-Paul M.C., Guzman-Granier E., Hastier P., Pradier C., et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur. J. Gastroenterol. Hepatol. 2000, 12(9):989-993. Epub 2000/09/28.
275. Mehta P., Ploutz-Snyder R., Nandi J., Rawlins S.R., Sanderson S.O., Levine R.A. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am. J. Gastroenterol. 2008, 103(4):928-936. Epub 2008/03/29.
276. Arthur M.J.P., Fibrogenesis Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279(2):G245-G249.
277. Tsukada S., Parsons C.J., Rippe R.A. Mechanisms of liver fibrosis. Clin. Chim. Acta 2006, 364(1-2):33-60. Epub 2005/09/06.
278. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274(31):21491-21494. Epub 1999/07/27.
279. Leroy V., Monier F., Bottari S., Trocme C., Sturm N., Hilleret M.N., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 2004, 99(2):271-279. Epub 2004/03/30.
280. Takahara T., Furui K., Funaki J., Nakayama Y., Itoh H., Miyabayashi C., et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995, 21(3):787-795. Epub 1995/03/01.
281. Takahara T., Furui K., Yata Y., Jin B., Zhang L.P., Nambu S., et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997, 26(6):1521-1529. Epub 1997/12/16.
282. Ueno T., Sujaku K., Tamaki S., Ogata R., Kin M., Nakamura T., et al. OK-432 treatment increases matrix metalloproteinase-9 production and improves dimethylnitrosamine-induced liver cirrhosis in rats. Int. J. Mol. Med. 1999, 3(5):497-503. Epub 1999/04/15.
283. Hayasaka A., Suzuki N., Fujimoto N., Iwama S., Fukuyama E., Kanda Y., et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996, 24(5):1058-1062. Epub 1996/11/01.
284. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996, 110(3):821-831. Epub 1996/03/01.
285. Walsh K.M., Timms P., Campbell S., MacSween R.N., Morris A.J. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig. Dis. Sci. 1999, 44(3):624-630. Epub 1999/03/18.
286. Boeker K.H., Haberkorn C.I., Michels D., Flemming P., Manns M.P., Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin. Chim. Acta 2002, 316(1-2):71-81. Epub 2001/12/26.
287. Annoni G., Weiner F.R., Zern M.A. Increased transforming growth factor-beta 1 gene expression in human liver disease. J. Hepatol. 1992, 14(2-3):259-264. Epub 1992/03/01.
288. Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 2002, 7:d793-d807. Epub 2002/03/19.
289. Nelson D.R., Gonzalez-Peralta R.P., Qian K., Xu Y., Marousis C.G., Davis G.L., et al. Transforming growth factor-beta 1 in chronic hepatitis C. J. Viral Hepat. 1997, 4(1):29-35. Epub 1997/01/01.
290. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. 2001, 15(10):1667-1672.
291. Koziel M.J. Cytokines in viral hepatitis. Semin. Liver Dis. 1999, 19(2):157-169. Epub 1999/07/28.
292. Chung Y.H., Kim J.A., Song B.C., Lee G.C., Koh M.S., Lee Y.S., et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000, 89(5):977-982. Epub 2000/08/30.
293. Harada K., Shiota G., Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999, 19(4):318-325. Epub 1999/08/25.
294. Canbay A., Friedman S., Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39(2):273-278. Epub 2004/02/10.
295. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443. Epub 2003/08/02.
296. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44(1):27-33.
297. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50(4):1072-1078.
298. Tamimi T.I., Elgouhari H.M., Alkhouri N., Yerian L.M., Berk M.P., Lopez R., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J. Hepatol. 2011, 54(6):1224-1229. Epub 2010/12/15.
299. Shen J.Y., Chan H.L.Y., Wong G.L.H., Choi P.C.L., Chan A.W.H., Chan H.Y., et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J. Hepatol. 2012, 56(6):1363-1370.
300. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 2009, 13(4):545-563.
301. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52(2):774-788. Epub 2010/08/05.
302. Neuschwander-Tetri B.A. Lifestyle modification as the primary treatment of NASH. Clin. Liver Dis. 2009, 13(4):649-665. Epub 2009/10/13.
303. Rogulj D., Konjevoda P., Milic M., Mladinic M., Domijan A.M. Fatty liver index as an indicator of metabolic syndrome. Clin. Biochem. 2012, 45(1-2):68-71.
304. Anstee Q.M., Daly A.K., Day C.P. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin. Liver Dis. 2011, 31(2):128-146. Epub 2011/05/04.
305. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142(4):711. 25 e6, Epub 2012/02/14.
306. Zimmer V., Lammert F. Genetics in liver disease: new concepts. Curr. Opin. Gastroenterol. 2011, 27(3):231-239. Epub 2011/04/01.
307. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40(12):1461-1465. Epub 2008/09/30.
308. He S., McPhaul C., Li J.Z., Garuti R., Kinch L., Grishin N.V., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 2010, 285(9):6706-6715. Epub 2009/12/26.
309. Petersen K.F., Dufour S., Hariri A., Nelson-Williams C., Foo J.N., Zhang X.M., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 362(12):1082-1089. Epub 2010/03/26.
310. Anstee Q.M., Daly A.K., Day C.P. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophys. Acta 2011, 1812(11):1557-1566. Epub 2011/08/16.
311. Tilg H., Moschen A. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13(4):391-396. Epub 2010/05/18.
312. Antya R., Lemoine M. Liver fibrogenesis and metabolic factors. Clin. Res. Hepatol. Gastroenterol. 2011, 35:S10-S20.
313. Hotta K., Yoneda M., Hyogo H., Ochi H., Mizusawa S., Ueno T., et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med. Genet. 2010, 11(1):172. Epub 2010/12/24.
314. Yoneda M., Hotta K., Nozaki Y., Endo H., Uchiyama T., Mawatari H., et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 2009, 29(7):1078-1085.
315. Boursier J., Louvet A. Liver fibrogenesis and genetic factors. Clin. Res. Hepatol. Gastroenterol. 2011, 35:S3-S9.